[Autoantibody-associated schizophreniform psychoses: pathophysiology, diagnostics, and treatment].

Autoantikörper-assoziierte schizophreniforme Psychosen: Pathophysiologie, Diagnostik und Therapie.

Journal

Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773

Informations de publication

Date de publication:
Jul 2019
Historique:
pubmed: 15 6 2019
medline: 12 9 2019
entrez: 15 6 2019
Statut: ppublish

Résumé

In the context of secondary, possibly organic schizophreniform psychoses, autoantibody(AB)-associated autoimmune encephalitis (AE) plays an increasingly important role. If this is suspected, clinical investigations, including laboratory, magnetic resonance imaging, electroencephalography and cerebrospinal fluid (CSF) analyses are recommended. The AB screening should include the most frequent ABs against neuronal cell surface antigens (NMDA receptor [R], CASPR2, LGI1, AMPA-R, GABAB-R), intracellular antigens (Hu, Ri, Yo, CV2/CRMP5, Ma2[Ta], amphiphysin, GAD65), thyroid tissue (TG, TPO, TRAK), and antinuclear antigens (ANAs). The ABs against cell surface antigens and GAD65 should be examined directly in serum and CSF. Less frequent ABs can be looked for in a second step. Furthermore, immunofluorescence tests on brain slices of rodents may identify previously unknown ABs. The detection of ABs in combination with further findings can lead to the diagnosis of AE which implies new therapeutic opportunities with immunomodulators.

Identifiants

pubmed: 31197396
doi: 10.1007/s00115-019-0735-1
pii: 10.1007/s00115-019-0735-1
doi:

Substances chimiques

Autoantibodies 0
Immunologic Factors 0

Types de publication

Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

745-761

Références

Ann Neurol. 2007 Jan;61(1):25-36
pubmed: 17262855
Neurology. 2012 May 29;78(22):1743-53
pubmed: 22539565
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Nervenarzt. 2013 Apr;84(4):461-5
pubmed: 23568167
Nervenarzt. 2013 Apr;84(4):466-70
pubmed: 23568168
J Neurol. 2013 Nov;260(11):2744-53
pubmed: 23900756
Neurohospitalist. 2013 Apr;3(2):53-64
pubmed: 23983888
Mol Psychiatry. 2014 Oct;19(10):1143-9
pubmed: 23999527
Lancet Neurol. 2014 Feb;13(2):167-77
pubmed: 24360484
Nervenarzt. 2014 Apr;85(4):485-98; quiz 499-501
pubmed: 24668402
Ann Neurol. 2014 Jul;76(1):82-94
pubmed: 24853231
Ann N Y Acad Sci. 2015 Mar;1338:94-114
pubmed: 25315420
Neuroscience. 2015 Nov 19;309:68-83
pubmed: 26012492
BMC Psychiatry. 2015 Aug 01;15:186
pubmed: 26231521
Int J Psychiatry Med. 2015;50(4):398-404
pubmed: 26644319
Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Mol Psychiatry. 2017 Dec;22(12):1776-1784
pubmed: 27502473
Brain. 2016 Oct;139(Pt 10):2641-2652
pubmed: 27543972
Neurol Neuroimmunol Neuroinflamm. 2016 Aug 29;3(5):e280
pubmed: 27606355
Autoimmun Rev. 2016 Dec;15(12):1129-1133
pubmed: 27639840
Nervenarzt. 2016 Dec;87(12):1293-1299
pubmed: 27847964
Lancet Psychiatry. 2017 Jan;4(1):42-48
pubmed: 27965002
Front Psychiatry. 2017 Feb 06;8:13
pubmed: 28220082
Neurology. 2017 Apr 4;88(14):1340-1348
pubmed: 28258082
Front Psychiatry. 2017 Feb 16;8:25
pubmed: 28261116
Physiol Rev. 2017 Apr;97(2):839-887
pubmed: 28298428
J Neuropsychiatry Clin Neurosci. 2017 Fall;29(4):365-374
pubmed: 28449636
Front Psychiatry. 2017 Apr 21;8:64
pubmed: 28484400
Psychosomatics. 2017 May - Jun;58(3):228-244
pubmed: 28545782
Neurol Neuroimmunol Neuroinflamm. 2017 Jul 18;4(5):e385
pubmed: 28761904
Biol Psychiatry. 2017 Nov 15;82(10):766-772
pubmed: 28780967
Nervenarzt. 2018 Jan;89(1):99-112
pubmed: 28932896
Ann Neurol. 2018 Jan;83(1):166-177
pubmed: 29293273
J Neuroinflammation. 2018 Feb 13;15(1):40
pubmed: 29433523
Nervenarzt. 2018 May;89(5):530-538
pubmed: 29523913
Nervenarzt. 2019 May;90(5):547-563
pubmed: 30968197
Front Psychiatry. 2019 Apr 25;10:226
pubmed: 31105597

Auteurs

Ludger Tebartz van Elst (L)

Sektion für experimentelle Neuropsychiatrie, Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Hauptstr. 5, 79104, Freiburg, Deutschland. tebartzvanelst@uniklinik-freiburg.de.

Karl Bechter (K)

Klinik für Psychiatrie und Psychotherapie II, Bezirkskrankenhaus Günzburg, Universität Ulm, Günzburg, Deutschland.

Harald Prüss (H)

Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Berlin, Berlin, Deutschland.
Experimentelle Neurologie und Klinik und Poliklinik für Neurologie, Charité Universitätsmedizin, Berlin, Deutschland.

Alkomiet Hasan (A)

Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, LMU, München, Deutschland.

Jo Hann Steiner (JH)

Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Deutschland.

Frank Leypoldt (F)

Institut für Klinische Chemie und Klinik für Neurologie, Universitätsklinik Schleswig-Holstein - Campus Kiel, Kiel, Deutschland.

Dominique Endres (D)

Sektion für experimentelle Neuropsychiatrie, Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Hauptstr. 5, 79104, Freiburg, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH